February 10, 2026 7:49am

“Uncle algo and his electronic trading dwarfs” are “smelling” the upside as data deluge appears coming

Investors are coming off dramatic gains to which I say BYE and SELL (some) into strength

News: Moderna (MRNA +$0.25 or +0.60% to $41.95 pre-open) signed a Memorandum of Understanding (MoU) for a long-term strategic agreement with the Mexican Government, Laboratorios de Biológicos y Reactivos de Mexico (BIRMEX), and Laboratorios Liomont (Liomont), to enhance Mexico's health sovereignty and mRNA manufacturing resilience. The 5-year agreement will include the supply of MRNA's respiratory vaccine portfolio, as well as technology transfer to Liomont, a Mexican pharmaceutical company with state-of-the-art manufacturing facilities, to produce mRNA-1273, MRNA's COVID-19 vaccine, and establish a reliable in-country supply of respiratory vaccines.

Pre-open Signals: Let the portfolio shake-out, if you understand probabilities, the inevitable is easier to maneuver

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t! 

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Monday’s RMi Closing Bell: Turn, turn and turn into coming earnings; also, will this week’s econs rotate a follow-on churn? … https://www.regmedinvestors.com/articles/14304

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The pre-open Dow futures are UP +0.02% or (+10 points), the S&P futures are UP +0.16% or (+11 points) and the Nasdaq futures are UP +0.23% or (+58 points)

  • U.S. stock futures are up yet skimpy on Tuesday. 2/10
  • European markets are mixed,
  • Asia Pacific markets mostly rose

 

Economic Data: Too many ...

December retail sales are expected to have jumped 0.4%, according to  consensus estimates. That compares to a 0.6% increase in the prior reading. Excluding autos, it’s expected to show a rise of 0.3%, versus a gain of 0.5% previously.

  • 6:00 am                NFIB optimism index      Jan.                        99.5        99.5
  • 8:30 am                Employment cost index Q4                          0.8%      0.8%
  • 8:30 am                Import price index (delayed report)         Dec.                       0.0%      NA
  • 8:30 am                Import price index minus fuel     Dec.                       --             NA
  • 8:30 am                U.S. retail sales (delayed report) Dec.                       0.4%      0.6%
  • 8:30 am                Retail sales minus autos Dec.                       0.3%      0.5%
  • 10:00 am             Business inventories (delayed report)     Nov.                      0.2%      0.3%
  • 12:00 pm             Cleveland Fed President Beth Hammack speaks                                                 
  • 1:00 pm               Dallas Fed President Lorie Logan speaks

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed UP +20.20 points or +0.04%, the S&P closed UP +32.51 points or +0.47% while the Nasdaq closed UP +207.457 points or +0.90%
  • Friday: The Dow closed UP +1206.95 points or +2.47%, the S&P closed UP +133.90 points or +1.97% while the Nasdaq closed UP +490.627 points or +2.18%
  • Last week: The S&P 500 closed down -0.1%, the Nasdaq fell -1.84% and the Dow rose +2.5%
  • The previous week: The S&P 500 closed up +0.04% and the Nasdaq -0.2%, while the Dow dropped -0.2%.
  • January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

 

Q1/26 – Q1 February – 3 positive and 3 negative closes

  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes  

Q4 – December,

  • 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Multiple earnings next week as sector releases Qs and FY25 …
  • Just wait, don't get caught with the "throw-away cards"!

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Expectation ... choppy trading, undrinkable econ “mash”, more earnings and still waiting for more late week econs as I prepare for more snow!

Since, the Q4 and FY25 earnings reporting cycle ….

  • Thursday - 2/12 - Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ultragenyx Pharmaceuticals (RARE)
  • Friday - 2/13 – Moderna (MRNA)
  • Tuesday - 2/24 – AxoGen (AXGN)

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

February – 2nd week

  • 2/9 -Monday closed positive with 23 incliners, 14 decliners and 3 flats

February continues …

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat
  • 2/3 - Tuesday closed negative with 18 incliners, 21 decliners and 1 flat    
  • 2/2 - Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.